Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
Earnings jump and dividend update put Marex Group (MRX) in focus
Marex Group (MRX) is back on investors' radar after reporting first quarter 2026 net income of US$112.4 million versus US$72.5 million a year earlier, alongside a quarterly dividend of US$0.16 per share.
See our latest analysis for Marex Group.
The earnings and dividend updates have arrived against a backdrop of strong momentum, with a 30 day share price return of 10.45% and a year to date share price return of 36.74%. The 1 year total shareholder return is 11.94% at a latest share price of US$51.88.
If this kind of move has you looking beyond a single stock, it could be a good moment to widen your search using the 19 top founder-led companies
With Marex Group trading at US$51.88 against an analyst price target of US$55.13, and an intrinsic value estimate that is higher than the current market price, should you view the stock as undervalued or already pricing in future growth?
Most Popular Narrative: 6% Undervalued
With Marex Group's most followed narrative pointing to a fair value of $55.00 against a last close of $51.88, the current valuation hinges on how investors view future margins, deal making, and geographic reach.
Ongoing M&A activity, particularly the transformative Winterflood acquisition and a robust pipeline of smaller deals, will drive both revenue and margin synergies through product/geographic diversification, cross-selling, and operational scale, positively impacting topline and earnings stability.
The fair value hinges on how quickly margins reshape, how deal activity filters into earnings, and how the model treats shrinking share count and weaker revenue trends.
Result: Fair Value of $55.00 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this narrative depends heavily on successful deal integration and on avoiding further regulatory or governance setbacks that could weaken margins and investor confidence.
Find out about the key risks to this Marex Group narrative.
Another View: DCF Signals Caution
While the most followed narrative sees Marex Group as about 6% undervalued at a fair value of $55.00, the SWS DCF model points the other way, with an estimate of $40.22. At a share price of $51.88, that model suggests the stock is trading above its future cash flow value. Which story do you put more weight on?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Marex Group for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With sentiment on Marex Group clearly mixed, use the latest figures and narratives to reach your own conclusion. Start with the 3 key rewards and 1 important warning sign .
Looking for more investment ideas?
If Marex Group has you thinking about what else might be out there, this is the moment to line up a few more ideas before the market moves on.
-
Spot potential value opportunities early by scanning 51 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their strengths.
-
Prioritise resilience by reviewing 72 resilient stocks with low risk scores that score well on financial health and may offer a smoother ride through market swings.
-
Get ahead of the crowd by searching the screener containing 23 high quality undiscovered gems for companies with strong under-the-radar potential before attention fully shifts their way.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MRX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
